🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

27 recruiting trials

for XLA

Observational Study Evaluating the Efficacy and Safety of Zanubrutinib in Participants With Waldenström Macroglobulinemia NCT05640102n/a8 sites📍 Huntsville📍 Mobile📍 Duarte BeiGene · Tests: Zanubrutinib Innovative Biomarkers of Cardiovascular Complications Associated With Second-generation Bruton Tyrosine Kinase Inhibitor Treatments: a Single-center Cohort Study NCT07174141n/a1 site📍 Dijon Centre Hospitalier Universitaire Dijon · Tests: Ophthalmological examination, Blood sample Implanted Loop Recorders for Detection and Management of Arrhythmia With Bruton Tyrosine Kinase Inhibitors NCT05643235NA1 site📍 New Hyde Park Northwell Health · Tests: Medtronic LINQ-2 Insertable Cardiac Monitor (ILR) A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma NCT06588478Phase 2131 sites📍 Chandler📍 Duarte📍 Irvine Loxo Oncology, Inc. · Tests: Pirtobrutinib Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader NCT05294731Phase 1, Phase 229 sites📍 Bengbu📍 Hefei📍 Beijing BeOne Medicines · Tests: Tacabrutideg Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Malignancies Undergoing Treatment With Bruton Tyrosine Kinase Inhibitors, the HALT Study NCT06151730n/a1 site📍 Rochester Mayo Clinic · Tests: Non-Interventional Study CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL) NCT03328078Phase 1, Phase 245 sites📍 Phoenix📍 Phoenix📍 Duarte Curis, Inc. · Tests: Emavusertib, Ibrutinib Determinants of the Response to BTK Degraders (BTKd) in Chronic Lymphocytic Leukemia NCT07099443n/a14 sites📍 Angers📍 Bordeaux📍 Bordeaux Nantes University Hospital · Tests: Non-Interventional Sample Collection and Analysis A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma NCT06973187Phase 3217 sites📍 Birmingham📍 Phoenix📍 Irvine BeOne Medicines · Tests: Tacabrutideg, Pirtobrutinib A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies NCT04830137Phase 116 sites📍 Duarte📍 Orange📍 San Francisco Nurix Therapeutics, Inc. · Tests: NX-2127 A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies NCT05131022Phase 162 sites📍 Duarte📍 San Francisco📍 Denver Nurix Therapeutics, Inc. · Tests: NX-5948 Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer NCT05106296Phase 11 site📍 Augusta Theodore S. Johnson · Tests: Indoximod, Ibrutinib, Cyclophosphamide, Etoposide, Ibrutinib A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies NCT05780034Phase 19 sites📍 Denver📍 Sarasota📍 Chapel Hill Accutar Biotechnology Inc · Tests: AC676 A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia NCT07277231Phase 3115 sites📍 Duarte📍 Orange📍 Palo Alto BeOne Medicines · Tests: Sonrotoclax, Zanubrutinib, Acalabrutinib, Venetoclax A Phase 2 Trial Of The Bruton Tyrosine Kinase Degrader BGB-16673 In Combination With BCL-2 Inhibitor Sonrotoclax For Patients With Treatment-Naive Chronic Lymphocytic Leukemia (CLL) NCT07508995Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: BGB-16673, BGB-11417 LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies NCT05990465Phase 11 site📍 Milwaukee Medical College of Wisconsin · Tests: Pirtobrutinib, LV20.19 CAR T cells A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors NCT06846671Phase 3132 sites📍 Jonesboro📍 Los Angeles📍 San Diego BeOne Medicines · Tests: Tacabrutideg, Bendamustine, Idelalisib, Rituximab, Venetoclax IGNITE: Study of Tirabrutinib vs Rituximab and Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) NCT07104032Phase 338 sites📍 Phoenix📍 Scottsdale📍 Fullerton Ono Pharmaceutical Co., Ltd. · Tests: Tirabrutinib, Rituximab, Temozolomide Analysis of the Role of IgE Proteoforms in Health and Disease NCT07328178n/a1 site📍 Leuven KU Leuven · Tests: Blood sample collection A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies NCT07271667Phase 211 sites📍 Miami Beach📍 Rochester📍 Florham Park Curis, Inc. · Tests: Emavusertib, Zanubrutinib Immune Regulation in Patients With Common Variable Immunodeficiency and Related Inborn Errors of Immunity (IEI) NCT00001244n/a1 site📍 Bethesda National Institute of Allergy and Infectious Diseases (NIAI… A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201) NCT07221500Phase 240 sites📍 Phoenix📍 Duarte📍 Los Angeles Nurix Therapeutics, Inc. · Tests: NX-5948 A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies NCT06634589Phase 1, Phase 249 sites📍 Phoenix📍 Los Angeles📍 Jacksonville BeOne Medicines · Tests: Tacabrutideg, Sonrotoclax, Zanubrutinib, Mosunetuzumab, Glofitamab A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies NCT05006716Phase 1, Phase 2114 sites📍 Birmingham📍 Phoenix📍 Scottsdale BeOne Medicines · Tests: Tacabrutideg Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia NCT06333262Phase 24 sites📍 Scarborough📍 Boston📍 Boston Inhye Ahn · Tests: Pirtobrutinib, Obinutuzumab A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) NCT06520098Phase 24 sites📍 San Francisco📍 Kansas City📍 Durham VA Office of Research and Development · Tests: Venetoclax, Ibrutinib, Acalabrutinib, Zanubrutinib Clonal Dynamics of Chronic Lymphocytic Leukaemia Treated With Pirtobrutinib After Previous Treatment With Zanubrutinib NCT06812715Phase 23 sites📍 Melbourne📍 Melbourne📍 Melbourne Peter MacCallum Cancer Centre, Australia · Tests: Pirtobrutinib
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy